Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer, and breast cancer. Provectus’ investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers.

Biotechnology

Provectus Biopharmaceuticals

Provectus Biopharmaceuticals' headquarters in Knoxville, TN, United States

Tim Scott

Heather Raines

Eric Wachter

Bruce Horowitz

Frank H. Akers

Ed Pershing

John Lacey, III

Harold Schmitz

Dominic Rodrigues

Webster Bailey

The Leadership Team at Provectus Biopharmaceuticals is responsible for strategic decision-making and overall direction of the company, focusing on advancing innovative therapies for cancer treatment. This team, comprising key executives including the CEO, COO, CTO, and CFO, collaborates to drive the development of investigational drugs like PV-10, manage financial resources, and ensure operational excellence in bringing new oncology therapies to market.

Leadership Team

The Scientific Advisors at Provectus Biopharmaceuticals play a crucial role in guiding the research and development of innovative therapies for cancer treatment. They leverage their expertise to inform clinical strategies, assess scientific data, and ensure alignment with regulatory standards, ultimately enhancing the efficacy and safety of investigational drugs like PV-10. Through collaboration with the broader scientific community, they help position the company at the forefront of oncology advancements.

Provectus Biopharmaceuticals

Org chart

Board & advisors

Teams

Leadership Team

Scientific Advisors

Offices

Provectus Biopharmaceuticals

Org chart

Board & advisors

Teams

Leadership Team

Scientific Advisors

Offices

Related companies